EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites across Germany, Poland, and Spain.
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other ...
Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences gains after GP2 commercial manufacturing update
Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2.
Finanznachrichten8d
Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Commercial Manufacturing
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Investing16d
Greenwich LifeSciences expands trial sites in Germany
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $161 million, has announced the initiation of clinical sites in Germany for its ...